Management of New Onset Third-Degree Heart Block

Immediate Assessment and Stabilization

The American Heart Association recommends rapidly assessing hemodynamic stability by evaluating for signs of poor perfusion, including acute altered mental status 1
Basic supportive measures should be initiated immediately, including maintaining a patent airway, assisting breathing as necessary, administering supplemental oxygen if hypoxemic, establishing IV access, attaching cardiac monitor and pulse oximetry, and obtaining a 12-lead ECG to assess QRS width and identify underlying rhythm 1, 2

The QRS complex width on the ECG is crucial for prognosis and treatment, with a wide QRS complex (>120 ms) indicating infranodal block, which carries high mortality risk and will not respond to atropine 1, 2, 3
A narrow QRS complex suggests AV nodal level block, though still requires pacing in most cases 3

The American College of Cardiology states that atropine should be avoided or used with extreme caution in third-degree AV block, as it is ineffective for infranodal blocks and may paradoxically worsen the block in some cases 1, 2, 4
If attempted in hemodynamically unstable patients while preparing for pacing, atropine should be used with caution, at a dose of 0.5 mg IV every 3-5 minutes (maximum 3 mg total), but should not delay pacing 1, 2

The American Heart Association recommends initiating transcutaneous pacing (TCP) immediately for symptomatic patients, as it is the preferred initial intervention for hemodynamically unstable third-degree AV block 1, 2
Permanent pacemaker implantation is a Class I indication, as stated in the 2018 ACC/AHA/HRS Guidelines, which recommend permanent pacing in patients with acquired second-degree Mobitz type II atrioventricular block, high-grade atrioventricular block, or third-degree atrioventricular block not attributable to reversible or physiologic causes 5, 3

The American College of Cardiology warns against relying on atropine as primary therapy for third-degree AV block, especially with wide QRS, as this delays definitive treatment 1, 2
Pacing should not be delayed for pharmacologic trials in hemodynamically unstable patients, and atropine administration should not delay TCP implementation 1, 2

The ACC/AHA guideline classifies atropine as a Class III (contraindicated) agent for third‑degree AV block at the His‑Purkinje level, especially when a new wide QRS complex is present. This reflects that atropine is ineffective for infranodal blocks and may worsen bradycardia by increasing sinus rate without ventricular capture. 6
Atropine should not be used as a primary therapy for nausea/vomiting in patients with complete heart block, because it does not address the underlying hemodynamic compromise and can delay definitive pacing. 6
A narrow exception exists: when nausea or vomiting is caused by morphine administration during an acute myocardial infarction, atropine is a Class I indication (recommended) to counteract morphine‑induced vagotonic effects. This indication is specific to morphine‑related symptoms, not to nausea arising from the heart block itself. 6

5‑HT₃ receptor antagonists (e.g., ondansetron 4–8 mg IV or granisetron 1 mg IV) are considered safe anti‑emetic options in patients with third‑degree AV block because they do not affect cardiac conduction. Use is recommended only after pacing has restored hemodynamic stability. 7
Phenothiazine agents (e.g., prochlorperazine) and dopamine antagonists (e.g., metoclopramide) should be avoided until cardiac stability is confirmed, as they possess potential cardiovascular effects that could exacerbate conduction abnormalities. 7